Icatibant Teva

Icatibant acetate, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous injection solution for subcutaneous administration. It is indicated for the treatment of acute attacks of hereditary angioedema in adult patients, providing rapid symptom relief.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution across multiple markets.

Icatibant Teva is used to manage hereditary angioedema, a disorder driven by excessive bradykinin activity.

Hereditary angioedema type I: Reduces swelling by blocking bradykinin B2 receptors during acute episodes. Hereditary angioedema type II: Provides rapid relief of symptoms by inhibiting bradykinin‑mediated vascular permeability. Acute HAE attacks in adults: Offers prompt control of edema and associated discomfort.

Icatibant Teva may cause a range of adverse reactions following subcutaneous injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling in other body parts. - Urticaria: hives or skin rash. - Thrombocytopenia: low platelet count, monitored via blood tests. - Severe injection‑site infection: signs of cellulitis or abscess.

Before using Icatibant Teva, several safety considerations should be observed. - Confirm diagnosis: ensure the patient has hereditary angioedema before administration. - Allergy assessment: avoid use in individuals with known hypersensitivity to icatibant or excipients. - Pregnancy: prescribe only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: evaluate the risk‑benefit ratio before use in nursing mothers. - Concomitant ACE inhibitor therapy: monitor closely as combined effects on bradykinin may occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Teva can interact with other medicines that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and diminish icatibant efficacy. - C1‑esterase inhibitor prophylaxis: concurrent use can complicate assessment of therapeutic response.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may affect frequency of HAE attacks. - Other B2 receptor antagonists: additive pharmacologic effects possible. - Diuretics: monitor blood pressure and electrolyte balance during therapy.